Nuix had information in January 2021 which undermined the growth story presented to the market in the prospectus for its IPO, a court has heard on the first day of ASIC’s case against the tech company and a handful of former directors.
A top orthopaedic surgeon who is suing Nine for defamation has accused the outlet of contempt of court by publishing unadmitted evidence about his reputation, claiming the stories were “improper, unjust and lacking in bona fides”.
NAB unit NULIS Nominees was not only allowed to charge superannuation fund members fees for adviser commissions, it was “obliged” to do so, a court has heard during a class action trial over alleged conflicted remuneration.
NAB unit NULIS Nominees was “hopelessly conflicted” in continuing to charge allegedly unlawful adviser commissions to superannuation fund members, a court has heard on the first day of a class action trial.
Finder Wallet has argued it did not need a financial services licence to sell its crypto product Finder Earn because it was not money, but instead allowed customers to purchase an asset and acted as a marketing tool to funnel users to its app.
General Motors has been accused of having “carefully curated” its list of witnesses to avoid giving evidence about the car maker’s decision to stop supplying Holden-branded vehicles in Australia, as trial in a class action by Holden dealers kicks off.
Federal environment minister Tanya Plibersek’s decision to greenlight the expansion of two mega coal mines in NSW was contrary to findings by the “entire community of climate scientists around the globe”, a court has heard.
On the first day of a seven-week trial, the applicant in a class action against Monsanto has taken aim at the agrochemical giant’s “same old approach” to undermining decades of evidence it says demonstrates the cancer-causing properties of popular weed killer Roundup.
A top orthopaedic surgeon and former NSW Australian of the year has argued in his defamation case against Nine that stories detailing his alleged negligence misled the public about medical issues and were the “opposite of public interest” journalism.
Agrochemical giant Monsanto is digging in for a fight in a class action over its alleged carcinogenic weed killer, Roundup, having refused to budge in mediation despite a $16 billion settlement in the US.